abstract |
The invention discloses that systemic activation of dopamine 3 receptor (D3R) significantly delays gastric emptying in rat, suggesting that D3R plays an important role in the regulation of gastric motility. Specific D3R antagonist, nafadotride, was shown to partially reverse the effect of dopamine on gastric emptying. The invention also discloses that D3R agonists and antagonists can be used to treat gastrointestinal motility disorders. |